Background-Thrombosis may be an important effector mechanism in the pathogenesis of Crohn's disease. Methods-This study therefore investigated the prevalence of independent thrombotic risk factors (factor VII coagulant activity, lipoprotein (a), fibrinogen, plasma triglycerides, and smoking) in patients with Crohn's disease, ulcerative colitis, and normal controls. Results-In Crohn's disease (n=75), the mean plasma VII:C, lipoprotein (a) and fibrinogen concentrations were significantly greater than in the normal population (n=85). In ulcerative colitis (n=35), only the mean factor VII:C concentration was significantly higher than normal. Ninety three per cent of patients with Crohn's disease and 86% of those with ulcerative colitis had at least one risk factor for thrombotic vascular disease, compared with 61% of the normal population (p<0.001). Conclusions-In many young patients with inflammatory bowel disease, plasma concentrations of these prothrombotic factors were in excess ofthe limits that are regarded as posing an increased risk for the development of occlusive vascular disease. (Gut 1996; 38: 733-737) 
Crohn's disease is associated with a granulomatous vasculitis and deposition of fibrin is a component of this inflammatory process. 2We reported the presence of microthrombi in rectal biopsy specimens from patients presenting with either ulcerative colitis or Crohn's disease, which may be present even in macroscopically normal mucosa without histological inflammation.3 In addition, the incidence of systemic thromboembolic events in inflammatory bowel disease is reported to be higher than in the normal population,45 a finding that is reinforced by postmortem studies.6 The increased risk of thrombosis has been attributed to a hypercoagulable state, the nature of which has yet to be elucidated-9 Despite evidence for activation of haemostasis in both Crohn's disease and ulcerative colitis, these conditions have been associated only rarely with a recognised primary abnormality of coagulation.78
Several independent risk factors for thrombotic vascular disease have been identified recently.9-11 Meade et al reported that high plasma factor VII coagulant activity (VII:C) is associated with an increased risk of an ischaemic myocardial event in male subjects over 40 years of age.9 In this study the mean plasma concentration of VII:C associated with an increased risk of a non-fatal myocardial event was 113 ,u/dl (in men over 40 years of age). An increase in VII:C of one standard deviation above the mean was associated with a 62% increased risk of an episode of ischaemic heart disease within five years. VII:C is a measure of the state of functional activity of factor VII in plasma and has been shown to correlate with thrombin generation. Assay procedures Plasma VII:C -the assay for VII:C is a one stage parallel line bioassay based on the prothrombin time. 16 Reagents: factor VII-deficient plasma (Diagen, Manchester, UK), thromboplastin (rabbit brain, Diagen) diluted 1/20, CaCl2 25 mM, Owren's buffered saline, standard (immuno 100% reference plasma, Vienna, Austria). Three dilutions (1/10, 1/20, and 1/40) of standard and test plasma samples were made; 0-1 ml of dilution, 0.1 ml of diluted thromboplastin, and 0.1 ml of factor VII deficient plasma were incubated together for two minutes. Then 0.1 ml of 25 mM CaCl2 was added and the clotting time measured using a KC 10 coagulometer (Brownes, Theale, Reading, UK).
Plasma triglycerides -to examine the potential interaction of plasma triglyceride concentration with plasma VII:C concentration,'7 the former was measured on each plasma sample, using an enzymic colorimetric test kit (Boehringer Mannheim, Lewes, UK). Plasma fibrinogen concentration was measured by the Clauss method,18 using bovine thrombin (Brownes) and Owren's buffered saline.
Plasma Lp(a) concentration was measured by ELISA (Biopool, Cambridge, UK). To examine for potential antifibrinolytic activity of LP(a), fibrinolytic activity was measured by estimation of d-dimer concentration by ELISA (Porton, Newmarket, UK). D-dimer is released from cross linked fibrin and is a sensitive marker of reactive fibrinolysis.19 20 C reactive protein was measured in each patient with Crohn's disease as confirmation of disease activity.
Results
Concentrations of plasma VII:C were significantly higher in patients with either Crohn's disease or ulcerative colitis compared with the normal population ( Table I ). The greatest difference was seen in the Crohn's disease patients (Figs 1 and 2) . Figure 3 shows a significant positive correlation between age and plasma VII:C concentration in both the healthy subjects and those with inflammatory bowel disease. The regression lines are almost parallel with the inflammatory bowel disease patients, at any age, having approximately a 20 U/dl increase in plasma VII:C compared with the normal subjects. In the Crohn's population VII:C did not correlate with disease activity determined by either the Harvey-Bradshaw score (Spearman, p=0.97) or the C reactive protein (Spearman, p=0.43). Nor was there any significant correlation between VII:C and fibrinogen (Spearman, p=0.3). There was no significant difference between VII:C in active and quiescent ulcerative colitis (Mann-Whitney U; p=0 4). Smoking did not seem to affect VII:C concentrations (Table II) . None of the inflammatory bowel disease patients was taking oral contraceptives, but one patient with Crohn's disease was receiving hormone replacement therapy. In the normal women the mean plasma VII:C concentration was not higher in those taking an oral contraceptive or hormone replacement therapy (n= 11, mean (SD) 102 (30) U/dl) compared with the remainder (n=36, 106 (21) U/dl).
There was no significant difference between the mean plasma triglyceride concentration in the patients with inflammatory bowel disease and the normal population (Table I) . There was no significant correlation between the plasma concentrations of triglyceride and either VII:C, Lp(a) or fibrinogen concentration in the normal population (Spearman, p>005 in all cases). In the female patients with Crohn's disease, however, the plasma triglyceride concentration correlated significantly with the plasma VII:C concentration (Spearman, p=0 05).
Women with Crohn's disease had a mean Lp(a) concentration that was significantly increased compared with the normal population (Table I) This study identifies a large number of young patients with inflammatory bowel disease, with values of VII:C (Fig 3) and Lp(a) at or above proposed values of excess risk for thrombotic vascular disease (Table III) .
The men with Crohn's disease had a significantly higher mean plasma fibrinogen concentration than the normal population (Table I) There is no evidence that the plasma VII:C concentration is an acute phase reactant,23 and this is supported by the lack of correlation with either disease activity, C reactive protein or fibrinogen in patients with Crohn's disease in this study. Although there is little that has been cited in published reports on VII:C in inflammatory disorders, a study in postoperative patients (non-inflammatory bowel disease) described a fall in plasma VII:C concentration after surgery.23 male and female populations, although in the female Crohn's patients a significant correlation (p<0 05) with VII:C was seen. Overall, however, there was no significant difference in plasma triglyceride concentrations between the normal population and the Crohn's disease patients.
It is possible that plasma VII:C concentration is increased in patients with inflammatory bowel disease by enhanced activation via the contact (intrinsic) system -that is, kinins and kininogens from the inflamed intestine activating factor XII and indirectly activating factor VII via factor IX. Should this be the case, the lack of correlation with clinical disease activity would suggest that this is an 'on-going' process, also activated during periods of apparent clinical remission. Alternatively there is evidence that plasma VII:C concentration may be genetically determined,24 and it is possible that this contributes to the recognised genetic risk that is associated with inflammatory bowel disease, a predisposition that has yet to be fully explained. 25 Although no conclusive evidence exists for the functional role of Lp(a) in atherosclerosis or other occlusive vascular disorders, there is abundant circumstantial evidence to link the two. Lp(a) has a structure closely related to low density lipoprotein, in that it consists of low density lipoprotein with an additional disulphide-linked apolipoprotein, apo (a).26 Apo (a) resembles plasminogen, the latter consisting offive different 'kringle' regions: apo (a) consists of kringle region 4 repeated between 13 and 37 times, and a kringle 5 subunit. It is the homology between the kringle 4 15 (18) 20 (27) 6 (17) Smoke (%) 19 (21) 24 ( X2=22-75, p<0-001***, X2=6-9, p<0-01**. 38 The results of this study suggest that many patients with either Crohn's disease or ulcerative colitis are exposed to a procoagulant and potentially antifibrinolytic environment. To our knowledge there is no reported increased incidence of ischaemic heart disease in patients with inflammatory bowel disease. In a study by Talbot et 
